EGFR and non-small cell lung carcinoma: At the same time, tumors harboring EGFR mutations demonstrated a higher rate of PD-L1 positivity compared to NSCLC with no genetic findings (p = 0.029), specifically in patients with LUAD (p = 0.015), but not SCC (p = 0.441; Supplementary Table S4).